With the discovery and development of tyrosine kinase inhibitors (TKIs), the clinical treatment strategy for advanced activating EGFR mutation lung adenocarcinoma has evolved into a personalized approach (4, 5). This evidence concerns the gene EGFR and lung adenocarcinoma.